Moderate to Severe

Juvenile Idiopathic Arthritis

Non-Infectious

Intermediate, Posterior and Panuveitis

Active

Psoriatic Arthritis

Moderate to Severe

Hidradenitis Suppurativa

Refractory, Moderate to Severe

Atopic Dermatitis

Gastroenterology

Moderate to Severe

Crohn's Disease

Moderate to Severe

Pediatric Crohn's Disease

Moderate to Severe

Ulcerative Colitis

Moderate to Severe

Pediatric Ulcerative Colitis

Ophthalmology

Non-Infectious

Intermediate, Posterior and Panuveitis

For moderate to severe rheumatoid arthritis (RA) in adult TNFi-IR patients1

Abbvie's commitment to
exceptional
access and patient
support

Get started with the
Enrollment & Prescription Form

RINVOQ is for moderate to severe rheumatoid arthritis (RA) in adult TNFi-IR patients1

>95% preferred
national commercial coverage

Preferred coverage means the product is placed on the plan's preferred formulary requirement of a prior TIM (including a TNFi) failure before starting RINVOQ

Preferred Commercial Coverage Preferred Commercial Coverage Preferred Commercial Coverage

Preferred coverage also could mean a STANDARD PRIOR AUTHORIZATION (PA) and APPEALS PROCESS, potential for one-time PA/appeal approval.

*Coverage requirements and benefit designs vary by payer and may change over time. Please consult with payers directly for the most current reimbursement policies.
TIM=targeted immunomodulator

Preferred coverage also could mean a
STANDARD PRIOR AUTHORIZATION (PA)
and APPEALS PROCESS, potential for one-time PA/appeal approval.

Commercial plan preferred formulary status for 2L TIM therapies for moderate to severe RA under the pharmacy benefit in 20212

National commercial plan formulary status under the pharmacy benefit National commercial plan formulary status under the pharmacy benefit National commercial plan formulary status under the pharmacy benefit

Cimzia, Actemra, and Orencia are available as products on medical benefits plans.3-5

Most national and regional health plans may not approve non-preferred products for patients who have shown clinical stability solely through the use of samples or other free goods.

The products listed here are not interchangeable and are not pharmaceutically equivalent or bioequivalent. They differ with respect to active and inactive ingredients, strength, dosage, indications, clinical efficacy, clinical safety, and line of therapy.

No conclusions regarding comparative safety or efficacy can be drawn from this information. Selection of a treatment regimen should be individualized for each patient based on factors including, but not limited to, product efficacy, product safety profile, adverse events, dosage and administration, potential for drug interactions, patients’ test results, and comorbid conditions.

*Coverage requirements and benefit designs vary by payer and may change over time. Please consult with payers directly for the most current reimbursement policies.
TIM=targeted immunomodulator

Please see HUMIRA full Prescribing Information.

Look up commercial insurance plans for RINVOQ in your area:

    Increasing 
    Medicare PART D coverage to
    RINVOQ® (upadacitinib) FOR APPROPRIATE PATIENTS2

    Medicare coverage is increasing Medicare coverage is increasing Medicare coverage is increasing

    Medicare Part D plan preferred formulary status for 2L TIM therapies for moderate to severe RA under the pharmacy benefit in 20212

    National commercial plan formulary status under the pharmacy benefit National commercial plan formulary status under the pharmacy benefit National commercial plan formulary status under the pharmacy benefit

    Cimzia, Actemra, and Orencia are available as products on medical benefits plans.3-5

    The products here are not interchangeable and are not pharmaceutically equivalent or bioequivalent. They differ with respect to active and inactive ingredients, strength, dosage, indications, clinical efficacy, clinical safety, and line of therapy.

    No conclusions regarding comparative safety or efficacy can be drawn from this information. Selection of a treatment regimen should be individualized for each patient based on factors including, but not limited to, product efficacy, adverse events, dosage and administration, potential for drug interactions, patients’ test results, and comorbid conditions.

    Please see HUMIRA full Prescribing Information.

    Two products.
    One exceptional patient experience.

    RINVOQ® COMPLETE
    HUMIRA® COMPLETE

    NURSE
    AMBASSADORS*

    Empower patients

    Our Nurse Ambassadors are the heart of RINVOQ Complete and HUMIRA Complete

    Nurse Ambassadors provide 1:1 support to help patients start and stay on track with their prescribed treatment plan, including:

    • Help patients understand the importance of following the treatment plan prescribed by their healthcare professional.
    • Committed to answering questions throughout the experience to help limit treatment disruptions.
    • Answer patients’ insurance questions and connect them with additional insurance expertise.
    • Identify ways for patients to save on prescription costs.

    ACCESS
    SPECIALISTS

    Insurance support when needed

    • Resource with expertise on Medicare and commercial plans at a national, local, and program level so that they can educate on potential options to consider based on each patient’s unique financial situation.
    • Can educate on payer prior authorization and appeal processes so you can determine the best access option for each patient’s unique situation.

    ACCESS & SAVINGS

    Help with access &
    treatment affordability

    COMPLETE can help your commercial patients save: 

    • With the Complete Savings Card, your eligible commercially insured patients may pay as little as $5 per month.
    • Complete may help eligible commercially insured patients experiencing initial coverage delays or denials access their prescribed therapy at no charge while coverage is established.

    Empowering Patients
    Nurse Ambassadors, In Their Own Words

    Have questions or need support over the phone?

    Call 1-877-COMPLETE (1‑800‑274‑6867)

    *Nurse Ambassadors are provided by AbbVie and do not provide medical advice or work under the direction of the prescribing healthcare professional (HCP). They are trained to direct patients to speak with their HCP about any treatment-related questions, including further referrals.

    RINVOQ Complete: Terms and Conditions apply. This benefit covers RINVOQ® (upadacitinib) alone or for RINVOQ plus one of the following medications: methotrexate, leflunomide (Arava®), or hydroxychloroquine (Plaquenil®). Eligibility: Available to patients with commercial prescription insurance coverage for RINVOQ who meet eligibility criteria. Co‑pay assistance program is not available to patients receiving prescription reimbursement under any federal, state, or government‑funded insurance programs (for example, Medicare [including Part D], Medicare Advantage, Medigap, Medicaid, TRICARE, Department of Defense, or Veterans Affairs programs) or where prohibited by law or by the patient’s health insurance provider. If at any time a patient begins receiving prescription drug coverage under any such federal, state, or government‑funded healthcare program, patient will no longer be able to use the RINVOQ Complete Savings Card and patient must call RINVOQ Complete at 1.800.2RINVOQ to stop participation. Patients residing in or receiving treatment in certain states may not be eligible. Patients may not seek reimbursement for value received from the RINVOQ Complete program from any third-party payers. Offer subject to change or discontinuance without notice. Restrictions, including monthly maximums, may apply. Patients who are members of insurance plans that claim to reduce or eliminate their patients' out-of-pocket co-pay, co-insurance, or deductible obligations for certain prescription drugs based upon the availability of, or patient's enrollment in, manufacturer sponsored co-pay assistance for such drugs (often termed "maximizer" programs) will have an annual maximum program benefit of $6,000.00 per calendar year. This assistance offer is not health insurance. To learn about AbbVie’s privacy practices and your privacy choices, visit www.abbvie.com/privacy.html

    HUMIRA Complete: Terms and Conditions apply. This benefit covers HUMIRA® (adalimumab) alone or, for rheumatology patients, HUMIRA plus one of the following medications: methotrexate, leflunomide (Arava®), or hydroxychloroquine (Plaquenil®). Eligibility: Available to patients with commercial prescription insurance coverage for HUMIRA who meet eligibility criteria. Copay assistance program is not available to patients receiving prescription reimbursement under any federal, state, or government‑funded insurance programs (for example, Medicare [including Part D], Medicare Advantage, Medigap, Medicaid, TRICARE, Department of Defense, or Veterans Affairs programs) or where prohibited by law or by the patient’s health insurance provider. If at any time a patient begins receiving prescription drug coverage under any such federal, state, or government‑funded healthcare program, patient will no longer be able to use the HUMIRA Complete Savings card and patient must call HUMIRA Complete at 1-800-4HUMIRA to stop participation. Patients residing in or receiving treatment in certain states may not be eligible. Patients may not seek reimbursement for value received from the HUMIRA Complete Program from any third-party payers. Offer subject to change or discontinuance without notice. Restrictions, including monthly maximums, may apply. Patients who are members of insurance plans that claim to reduce or eliminate their patients' out-of-pocket co-pay, co-insurance, or deductible obligations for certain prescription drugs based upon the availability of, or patient's enrollment in, manufacturer sponsored co-pay assistance for such drugs (often termed "maximizer" programs) will have an annual maximum program benefit of $6,000.00 per calendar year. This assistance offer is not health insurance. To learn about AbbVie’s privacy practices and your privacy choices, visit www.abbvie.com/privacy.html

    Arava® and Plaquenil® are registered trademarks of their respective owners.

    Program is not available to patients receiving prescription reimbursement under any federal, state, or government-funded insurance programs (for example, Medicare [including Part D], Medicare Advantage, Medigap, Medicaid, TRICARE, Department of Defense, or Veterans Affairs programs) or where prohibited by law or by the patient’s health insurance provider. If at any time a patient begins receiving prescription drug coverage under any such federal, state, or government-funded healthcare program, patient will no longer be eligible to participate in program. Available to patients between the ages of 18-63 with commercial prescription insurance coverage who meet eligibility criteria. Eligibility: Patients must be diagnosed with moderate to severe rheumatoid arthritis, have a valid prescription for RINVOQ® and participate in a commercial insurance plan that has denied or not yet made a formulary decision for RINVOQ. Once the patient’s insurance plan has made a formulary decision and established a process for reviewing coverage requests for RINVOQ, continued eligibility for the program requires the submission of a Prior Authorization prior to the next scheduled dose and appeal of the coverage denial within 180 days. Program provides RINVOQ at no charge to patients for up to 2 years or until they receive insurance coverage approval, whichever occurs earlier. Offer subject to change or discontinuance without notice. This is not health insurance and program does not guarantee insurance coverage.

    How to enroll patients in the
    complete program

    Help patients get the support they need to start and stay
    on track with their prescribed treatment

    To enroll a patient in RINVOQ Complete:

    1

    Fill out the form with your patient
    This form enrolls your patient and can be used to initiate a prescription with your patient’s preferred specialty pharmacy.

    3

    Fax the form to 1-678-727-0690 and to the patient's chosen specialty pharmacy
    You will receive a call from an Access Specialist to discuss next steps. In addition, fax the form to your patient’s specialty pharmacy if using the Pharmacy Prescription in Section 9.

    2

    Fill out the patient support prescription in Section 6
    This may help your commercially insured patients get access to RINVOQ if they experience a delay or denial in their insurance coverage.*

    2

    Fill out the patient support prescription in
    Section 6

    This may help your commercially insured patients get access to RINVOQ if they experience a delay or denial in their insurance coverage.*

    3

    Fax the form to 1-678-727-0690 and to the patient's chosen specialty pharmacy
    You will receive a call from an Access Specialist to discuss next steps. In addition, fax the form to your patient’s specialty pharmacy if using the Pharmacy Prescription in Section 9.

    4

    Inform your patient that they have been enrolled
    Let your patient know that they will be receiving a call from their Nurse Ambassador.

    Please see HUMIRA full Prescribing Information.

    *Program is not available to patients receiving prescription reimbursement under any federal, state, or government‑funded insurance programs (for example, Medicare [including Part D], Medicare Advantage, Medigap, Medicaid, TRICARE, Department of Defense, or Veterans Affairs programs) or where prohibited by law or by the patient’s health insurance provider. If at any time a patient begins receiving prescription drug coverage under any such federal, state, or government‑funded healthcare program, patient will no longer be eligible to participate in program. Available to patients between the ages of 18-63 with commercial prescription insurance coverage who meet eligibility criteria. Eligibility: Patients must be diagnosed with moderate to severe rheumatoid arthritis, have a valid prescription for RINVOQ® and participate in a commercial insurance plan that has denied or not yet made a formulary decision for RINVOQ. Once the patient’s insurance plan has made a formulary decision and established a process for reviewing coverage requests for RINVOQ, continued eligibility for the program requires the submission of a Prior Authorization prior to the next scheduled dose and appeal of the coverage denial within 180 days. Program provides RINVOQ at no charge to patients for up to 2 years or until they receive insurance coverage approval, whichever occurs earlier. Offer subject to change or discontinuance without notice. This is not health insurance and program does not guarantee insurance coverage.

    Nurse Ambassadors are provided by AbbVie and do not provide medical advice or work under the direction of the prescribing healthcare professional (HCP). They are trained to direct patients to speak with their HCP about any treatment-related questions, including further referrals.

    Complete app

    COMPLETE APP

    Track treatment

    The Complete App helps patients stay on track with their prescribed RINVOQ or HUMIRA treatment by helping them:

    • Access additional resources, including a savings card for those that are eligible
    • Set customized medication reminders
    • Log and share symptoms with HCPs
    • Log medication lot number and medication expiration date
    Download on the App Store
    Get it on Google Play

    COMPLETEPRO.COM

    Streamline the Rx process

    CompletePro.com enables seamless enrollment into RINVOQ Complete and HUMIRA Complete, and helps streamline the prescription process for your patients.

     

    With CompletePro.com, you can:

    • Request benefits verifications
    • Complete and submit prior authorizations
    • Send prescriptions to the patient’s specialty pharmacy of choice, with the option to include a savings card
    • Receive alerts for annual reauthorizations and renewals
    • Track and monitor where patients are in the prescription process

    Learn more about streamlining the prescription process with Complete Pro:

    RINVOQ SAFETY DATA

    Review the well-studied safety profile of RINVOQ,
    including both short- and long-term analyses

    IMPORTANT SAFETY INFORMATION & INDICATION1

    INDICATION1

    RINVOQ is indicated for the treatment of adults with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to one or more TNF blockers.

    Limitation of Use: Use of RINVOQ in combination with other JAK inhibitors, biologic DMARDs, or with potent immunosuppressants, such as azathioprine and cyclosporine, is not recommended.

    SERIOUS INFECTIONS

    • Active tuberculosis (TB), which may present with pulmonary or extrapulmonary disease. Test patients for latent TB before RINVOQ use and during therapy. Consider treatment for latent TB infection prior to RINVOQ use.
    • Invasive fungal infections, including cryptococcosis and pneumocystosis.
    • Bacterial, viral, including herpes zoster, and other infections due to opportunistic pathogens.

    MORTALITY

    MALIGNANCIES

    MAJOR ADVERSE CARDIOVASCULAR EVENTS

    THROMBOSIS

    HYPERSENSITIVITY

    GASTROINTESTINAL PERFORATIONS

    LABORATORY ABNORMALITIES

    EMBRYO-FETAL TOXICITY

    VACCINATION

    LACTATION

    HEPATIC IMPAIRMENT

    ADVERSE REACTIONS

    REFERENCES

    1. RINVOQ [package insert]. North Chicago, IL: AbbVie Inc.
    2. Data on file, AbbVie Inc. Payer-reported lives. December 1, 2021.
    3. Cimzia [package insert]. Smyrna, GA: UCB Inc; 2019.
    4. Actemra [package insert]. South San Francisco, CA: Genentech, Inc; 2019.
    5. Orencia [package insert]. Princeton, NJ: Bristol-Myers Squibb Company; 2019.

    INDICATION & LIMITATION OF USE1

    RINVOQ is indicated for the treatment of adults with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to one or more TNF blockers.

    Limitation of Use: Use of RINVOQ in combination with other JAK inhibitors, biologic DMARDs, or with potent immunosuppressants, such as azathioprine and cyclosporine, is not recommended.

    IMPORTANT SAFETY INFORMATION1

    WARNING: Serious Infections, Mortality, Malignancies, Major Adverse Cardiovascular Events, and Thrombosis.

    SERIOUS INFECTIONS

    Patients treated with RINVOQ are at increased risk for developing serious infections that may lead to hospitalization or death. Most patients who developed these infections were taking concomitant

    IMPORTANT SAFETY INFORMATION1

    WARNING: Serious Infections, Mortality, Malignancies, Major Adverse Cardiovascular Events, and Thrombosis.

    SERIOUS INFECTIONS

    Patients treated with RINVOQ are at increased risk for developing serious infections that may lead to hospitalization or death. Most patients who developed these infections were taking concomitant

    INDICATION & LIMITATION OF USE1

    RINVOQ is indicated for the treatment of adults with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to one or more TNF blockers.

    Limitation of Use: Use of RINVOQ in combination with other JAK inhibitors, biologic DMARDs, or with potent immunosuppressants, such as azathioprine and cyclosporine, is not recommended.

    IMPORTANT SAFETY INFORMATION1

    WARNING: Serious Infections, Mortality, Malignancies, Major Adverse Cardiovascular Events, and Thrombosis.

    SERIOUS INFECTIONS

    Patients treated with RINVOQ are at increased risk for developing serious infections that may lead to hospitalization or death. Most patients who developed these infections were taking concomitant

    IMPORTANT SAFETY INFORMATION1

    WARNING: Serious Infections, Mortality, Malignancies, Major Adverse Cardiovascular Events, and Thrombosis.

    SERIOUS INFECTIONS

    Patients treated with RINVOQ are at increased risk for developing serious infections that may lead to hospitalization or death. Most patients who developed these infections were taking concomitant

    IMPORTANT SAFETY INFORMATION & INDICATION1

    INDICATION1

    RINVOQ is indicated for the treatment of adults with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to one or more TNF blockers.

    Limitation of Use: Use of RINVOQ in combination with other JAK inhibitors, biologic DMARDs, or with potent immunosuppressants, such as azathioprine and cyclosporine, is not recommended.

    SERIOUS INFECTIONS

    • Active tuberculosis (TB), which may present with pulmonary or extrapulmonary disease. Test patients for latent TB before RINVOQ use and during therapy. Consider treatment for latent TB infection prior to RINVOQ use.
    • Invasive fungal infections, including cryptococcosis and pneumocystosis.
    • Bacterial, viral, including herpes zoster, and other infections due to opportunistic pathogens.

    MORTALITY

    MALIGNANCIES

    MAJOR ADVERSE CARDIOVASCULAR EVENTS

    THROMBOSIS

    HYPERSENSITIVITY

    GASTROINTESTINAL PERFORATIONS

    LABORATORY ABNORMALITIES

    EMBRYO-FETAL TOXICITY

    VACCINATION

    LACTATION

    HEPATIC IMPAIRMENT

    ADVERSE REACTIONS